An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

ELIQUIS®

Drug Information Related Patent

Hold Company

BRISTOL MYERS SQUIBB

Learn More

Dosage and Administration

TABLET;ORAL

Specification

2.5MG; 5MG

Indication

ELIQUIS® can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Use

Instructions for Use

API

APIXABAN

API Structure

We Supply

APIXABAN

Note:

In-house Standard/CP/USP/EP/JP
Facility GMP
Product GMP
USMF/ASMF/CADMF/China DMF/DMF/WC/KDMF/CDE

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
6967208	2026/11/21
9326945	2031/2/24

API Patent

Patent No	Expiration Date
6967208	2026/11/21

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION